Wound Healing Effect of Tildipirosin on Bovine Tracheal Epithelial Cell

Abstract

This study aimed to investigate the in vitro wound healing effect of tildipirosin, used in treating bovine respiratory diseases, on bovine tracheal epithelial cells. With an in vitro wound method, a wounded area was created on bovine tracheal epithelial cells found in each well with a 200 μL pipette tip (vertical). Concentrations of tildipirosin (5 μg/mL, 10 μg/mL, 25 μg/mL, 50 μg/mL) and control group were applied on in vitro wound formed bovine tracheal epithelial cells. In vitro wound images were monitored at 0th, 24th and 48th hours. No statistically significant difference was found at 50 μg/mL concentration of tildipirosin at the 24th hour of the study regarding to wound healing area. In contrast, the difference was statistically significant at 5, 10, and 25 μg/mL concentrations of tildipirosin as compared to control group. At the 48th hour of the study, there was no statistically significant difference between 25 and 50 μg/mL concentrations of tildipirosin compared to the control group. In contrast, 5 μg/mL (%96,61±1,69) and 10 μg/mL (%96,42±1,78) tildipirosin statistically increased the wound healing percentage. To conclude, the wound healing rate (48th hour) at low concentrations of tildipirosin was approximately %96, and this may contribute to the protection and treatment of tissue integrity against epithelial cell damage by various microorganisms and substances in addition to the treatment of diseases.

Keywords

• Bovine
• In vitro
• Tildipirosin
• Tracheal epithelial cell
• Wound healing

Tildipirosinin Sığır Trakea Epitel Hücresi Üzerinde Yara İyileştirici Etkisi

Abstract

Bu çalışmada; sığır solunum yolu hastalıkları tedavisinde kullanılan tildipirosinin, sığır trakea epitel hücresi üzerinde in vitro yara iyileşmesi etkisinin araştırılması amaçlandı. In vitro yara yöntemi ile her kuyucuğa ekilmiş olan sığır trakea epitel hücreleri üzerinde, 200 μL’lik pipet ucu (dikey) aracılığıyla bir yara alanı oluşturuldu. In vitro yara oluşturulmuş sığır trakea epitel hücreleri üzerine tildipirosinin konsantrasyonları (5 μg/mL, 10 μg/mL, 25 μg/mL, 50 μg/mL) ve kontrol grubu uygulandı. In vitro yara görüntüleri; 0’ıncı saat, 24’üncü saat ve 48’inci saatte izlendi. Çalışmanın 24’üncü saatinde yara alanı kapanma yüzdesi, kontrol grubuna kıyasla; tildipirosinin 50 μg/mL konsantrasyonda istatistiki olarak önemli fark bulunamazken 5, 10 ve 25 μg/mL konsantrasyonlarında istatistiki olarak fark anlamlı bulundu. Çalışmanın 48’inci saatinde, kontrol grubuna kıyasla 25 ve 50 μg/mL tildipirosin konsantrasyonları arasında istatistiki olarak önemli fark bulunamazken, 5 μg/mL (%96,61±1,69) ve 10 μg/mL (%96,42±1,78) tildipirosin konsantrasyonları arasında yara alanı kapanma yüzdeleri arasında istatistiki olarak fark anlamlı bulundu. Sonuç olarak tildipirosinin düşük konsantrasyonlarındaki yara iyileşme yüzdelerinin (48’inci saat) yaklaşık olarak %96 olması, hastalıkların tedavisine ek olarak çeşitli mikroorganizma ve maddeler tarafından epitel hücrelerinde meydana gelen hasarlara karşı doku bütünlüğünü koruma ve tedaviye katkı sağlayabilir.

Keywords

• İn vitro
• Sığır
• Tildipirosin
• Trakea Epitel Hücresi
• Yara İyileşmesi

References

1. Anderson NM, Poehlsgaard J, Warrass R, Douthwaite S, 2012: Inhibition of protein synthesis on the ribosome by tildipirosin compared with other veterinary macrolides. Antimicrob Agents Chemother, 56 (11), 6033-6036.
2. Beckmann JD, Takizawa H, Romberger D, Illig M, Claassen L, Rickard K, Rennard SI, 1991: Serum-free culture of fracttionated bovine bronchial epithelial cells. In Vitro Cell Dev Biol, 28 (1), 39-46.
3. Benchaoui HA, Nowakowski M, Sherington J, Rowan TG, Sunderland SJ 2004: Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J Vet Pharmacol Ther, 27 (4), 203-210.
4. Bertuzzi M, Hayes GE, Bignell EM, 2019: Microbial uptake by the respiratory epithelium: outcomes for host and pathogen. FEMS Microbiol Rev, 43 (2), 145-61.
5. Čulić O, Eraković V, Parnham MJ, 2001: Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol, 429 (1-3), 209-229.
6. Fischer CD, Beatty JK, Zvaigzne CG, Morck DW, Lucas MJ, Buret AG, 2011: Anti-inflammatory benefits of antibiotic-induced neutrophil apoptosis: tulathromycin induces caspase-3-dependent neutrophil programmed cell death and inhibits NF-kappaB signaling and CXCL8 transcription. Antimicrob Agents Chemother, 55 (1), 338-348.
7. Galecio JS, Escudero E, Cerón JJ, Crescenzo G, Marín P, 2020: Pharmacokinetics of tildipirosin in ewes after intravenous, intramuscular and subcutaneous administration. Animals (Basel), 10 (8), 1332.
8. Giguère S, 2013: Macrolides, azalides, and ketolides In: Antimicrobial Therapy in Veterinary Medicine, Giguére S, Prescott JF, Dowling PM (Eds), 211-231, 5th ed., Wiley Blackwell, Lowa.

9. Gouzos M, Ramezanpur M, Bassiouni A, Psaltis AJ, Wormald PJ, Vreugde S, 2020: Antibiotics affect ROS production and fibroblast migration in an in-vitro model of sinonasal wound healing. Front Cell Infect Microbiol, 10, 110.
10. Guillot L, Tabary O, Nathan N, Corvol H, Clement A, 2011: Macrolides: New therapeutic perspectives in lung diseases. Int J Biochem Cell Biol, 43 (9), 1241-1246.
11. Ianaro A, Ialenti A, Maffia P, Sautebin L, Rombola L, Carnuccio R, Iuvone T, D’Acquisto F, Di Rosa M, 2000: Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther, 292 (1), 156-163.
12. Iosifidis T, Garratt LW, Coombe DR, Knight DA, Stick SM, Kicic A, 2016: Airway epithelial repair in health and disease: Orchestrator or simply a player?. Respirology, 21 (3), 438-48.
13. Kürüm A, Karahan S, Kocamış H, Çınar M, Ergün E, 2019: Determination of antioxidants in bovine oviduct epithelial cell culture isolated at different periods of the estrous cycle. Turk J Vet Anim Sci, 43, 448-455.
14. Lei Z, Liu Q, Qi Y, Yang B, Khaliq H, Xiong J, Moku GK, Ahmed S, Li K, Zhang H, Zhang W, Cao J, He Q, 2018: Optimal regimens and cutoff evaluation of tildipirosin against pasteurella multocida. Front. Pharmacol, 9, 765.
15. Leoni G, Neumann PA, Sumagin R, Denning TL, Nusrat A, 2015: Wound repair: role of immune–epithelial interactions. Mucosal Immunol, 8 (5), 958-968.
16. Mencucci R, Pellegrini-Giampietro DE, Paladini L, Favuzza E, Menchini U, Scartabelli T, 2013: Azithromycin: assessment of intrinsic cytotoxic effects on corneal epithelial cell cultures. Clin Ophthalmol, 7, 965-971.
17. Menge M, Rose M, Bohland C, Zschiesche E, Klip S, Metz W, Allan M, Röpke R, Nürnberger M, 2012: Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle). J Vet Pharmacol Ther, 35 (6), 550-559.
18. Nowakowski MA, Inskeep PB, Risk JE, Skogerboe TL, Benchaoui HA, Meinert TR, Sherington J, Sunderland SJ, 2004: Pharmacokinetics and lung tissue concentrations of tulathromycin, a new triamilide antibiotic, in cattle. Vet Ther, 5 (1), 60-74.
19. Papich MG, 2018: Chloramphenicaol and Derivatives, Macrolides, Lincosamides, and Miscellaneous Antimicrobials In: Veterinary Pharmacology and Therapeutics. Riviere JE, Papich MG, (eds), 903-52, 10th ed., John Wiley and Sons, Hoboken.
20. Peres PR, Prigol SR, Martín CBG, Feronatod C, Suriñach MC, Kreutz LC, Frandoloso R, 2020: Tildipirosin: An effective antibiotic against Glaesserella parasuis from an in vitro analysis. Vet Anim Sci, 10: 100136.
21. Pyörälä S, Baptiste KE, Catry B, Dujkeren EV, Greko C, Moreno MA, Pomba MCMF, Rantala M, Ružauskas M, Sanders P, Threlfall EJ, Torren-Edo J, Törneke K, 2014: Macrolides and lincomides in cattle and pigs: use and development of antimicrobial resistance. Vet J, 200 (2), 230-239.
22. Şahin Y, Yıldırım E, 2020: Antibiyotiklerin hücre içi farmakokinetik özellikleri, KÜ Tıp Fak Derg, 22 (3), 470-477.
23. Van Bambeke F, Barcia-Macay M, Lemaria S, Tulkens PM, 2006: Cellular pharmacodynamics and pharmacokinetics of antibiotics: Current views and perspectives. Curr Opin Drug Discov Devel, 9 (2), 218-30.
24. Wang X, Decker CC, Zechner L, Krstin S, wink M, 2019: In vitro wound healing of tumor cells: inhibition of cell migration by selected cytotoxic alkaloids. BMC Pharmacol Toxicol, 20 (1), 4.
25. Zeng D, Sun M, Lin Z, Li M, Gehring R, Zeng Z, 2018: Pharmacokinetics and pharmacodynamics of tildipirosin aganist pasteurella multocida in a murine lung infection model. Front Microbiol, 9, 1038.
26. Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky JA, 2001: Review of macrolides and ketolides: focus on respiratory tract infections. Drugs, 61 (4), 443-498.